Molecular modifications in factor VIII concentrates produced from different plasma pools

Thrombosis Research

Volumn 101, Issue 6, 2001, Pages 501-511

  Saenko, Evgueni ^a,b   Josic, Djuro ^c   Stadler, Monika ^c   Sarafanov, Andrei ^a   Lim, Yow Pin ^d   Shima, Midori ^e   Ananyeva, Natalya ^a   Schwinn, Horst ^f  

^a HOLLAND LABORATORY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Octapharma Pharmazeutika Produktions GmbH   (Austria)

^d RHODE ISLAND HOSPITAL   (United States)

^e NARA MEDICAL UNIVERSITY   (Japan)

^f Octapharma AG   (Switzerland)

Author keywords

Coagulation; Factor VIII; Haemophilia; Immunogenicity; Inhibitory antibody

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DETERGENT; PHOSPHOLIPID; SOLVENT;

ANTIBODY PRODUCTION; ARTICLE; BELGIUM; BLOOD ANALYSIS; BLOOD CLOTTING; FEMALE; GERMANY; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PASTEURIZATION; PRIORITY JOURNAL; VIRUS INACTIVATION;

ANTITHROMBIN III; DETERGENTS; FACTOR VIII; FIBRINOGEN; HEMOPHILIA A; HUMANS; PEPTIDE HYDROLASES; PHOSPHOLIPIDS; PLASMA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SOLVENTS; STERILIZATION;

EID: 0035868255     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00423-0     Document Type: Article

References (22)

1. The incidence of factor VIII inhibitors in patients with severe hemophilia A
2. The natural history of factor VIII inhibitors in patients with hemophilia A
3. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands
4. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
5. Factor VIII inhibitors in previously treated haemophilia A patients with a double-virus inactivated plasma derived factor VIII concentrate
6. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of fVIII light chain
7. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors
8. Inhibitor development and activated factor VIII in concentrates
9. Modification of factor VIII in therapeutic concentrates after virus inactivation by virus inactivation by solvent-detergent and pasteurisation
10. Degradation products of factor VIII which can lead to increased immunogenicity
11. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine
12. A role for the C2 domain of factor VIII in binding to von Willebrand factor
13. Biochemical and immunochemical investigations of different plasma-derived and recombinant factor VIII products
14. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives
15. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor
16. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
17. Standartization of assays of factor VIII and IX
18. Development of a simple chromogenic factor VIII assay for clinical use
19. A simple method for the preparation of homogeneous phospholipid vesicles
20. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
21. FPA content - A criterion of quality for plasma as factor VIII source
22. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid binding site